MYH9 and Macrothrombocytopenia: Of note, A+/AR702C mice and humans with mutations in NMHC II-A (including R702C) develop MYH9-related disease12, 13, 14, 15 which is characterized by macrothrombocytopenia and glomerulosclerosis but not by tumor development.